A Phase III Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of LUMINENZ-AT (CM-AT) in Children with Autism
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities
Target Audience:
Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
Geographic Areas, Rural/Remote, Urban
Primary Target Audience Geographic Descriptor:
Regional
COVID-19 Related Data:
N/A